Lutikizumab - CISMeF

Preferred Label : Lutikizumab;

NCIt definition : A dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1k) against the inflammatory cytokine human interleukin-1 alpha (IL-1a) and beta (IL-1b), with potential anti-inflammatory activity. Upon administration, lutikizumab targets, binds to, and neutralizes IL-1a/b thereby preventing the activity of IL-1a and IL-1b. This may inhibit IL1a/b-mediated inflammatory responses. This may reduce pain and slows tissue destruction and structural progression in diseases in which IL-1a/b are upregulated. IL1a/b, inflammatory mediators, play key roles in immune regulation and inflammatory processes.;

UNII : 15FAZ725S0;

CAS number : 1791411-57-8;

Molecule name : ABT-981; ABT 981;

NCI Metathesaurus CUI : CL971716;

Details

Origin ID

C166465;

UMLS CUI

C5226856;

Currated CISMeF NLP mapping
- Lutikizumab [SMS substance]
- lutikizumab [MeSH concept]
- lutikizumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- lutikizumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients